Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)

Fujian Haixi Pharmaceuticals

Status and phase

Enrolling

Phase 2

Phase 1

Conditions

Wet Age-related Macular Degeneration (AMD)

Treatments

Drug: HX9428 tablet

Study type

Interventional

Funder types

Industry

Identifiers

NCT07185841

HXP056-CTPI-01

Details and patient eligibility

About

This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of Oral HX9428 tablets in patients with wet age-related macular degeneration(wAMD)

Full description

This is a Multicenter, Open-label, Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral HX9428 tablets in Subjects with Wet Age-related Macular Degeneration (wAMD). The study consists of 2 segments: Phase I and Phase II. Phase I will evaluate the safety and tolerability of HX9428 administered as single and multiple oral doses; dose escalation will follow a 3 + 3 design with overdose control. If evidence of efficacy is observed at any dose level during Phase I, a parallel Phase II study may be initiated while dose-escalation in Phase I continues. In Phase II, the daily dose of HX9428 will not exceed the Maximum Tolerated Dose (MTD) established in Phase I; dosing frequency will be once daily (QD) or every other day (QOD).The primary objective of Phase II is to assess the preliminary efficacy of HX9428 tablets under these regimens.

Enrollment

198 estimated patients

Sex

All

Ages

50 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Participants must meet the following criteria for study entry:
1. Age ≥50 years and ≤80 years (Phase I), Age ≥50 years and ≤85 years (Phase II) at the time of signing informed consent, male or female;
2. Active choroidal neovascularization (CNV) secondary to AMD, as evidenced on fluorescein fundus angiography (FFA) and optical coherence tomography (OCT) (Active CNV is defined as the presence of subretinal or intraretinal fluid or leakage); A total lesion size of <12 disc areas on FFA ;
3. Treatment-naive , or previous anti-VEGF treatment that was effective and discontinued for more than 3 months, with OCT evidence of subretinal fluid or cystoid macular edema;
4. ETDRS BCVA 19 to 78 letters in the study eyes( corresponding to a Snellen equivalent of approximately 20/32 to 20/400) ;
5. Other protocol-specified inclusion criteria may apply

Exclusion criteria

Subjects who meet any of the following criteria will be excluded from this study:
1. Subjects diagnosed with polypoidal choroidal vasculopathy by Indocyanine Green(ICG) angiography who are at high risk of massive hemorrhage;
2. On FFA/CFP: subretinal hemorrhage of >50 % of the total lesion area or that involves the fovea; fibrosis or atrophy of >50 % of the total lesion area or that involves the fovea;
3. CNV due to causes other than AMD;
4. Any condition in the study eye that could compromise best-corrected visual acuity;
5. Active ocular inflammation or infection in either eye or a history of idiopathic or autoimmune-related uveitis;
6. Refractive error exceeding -6.00 D spherical equivalent;
7. Ocular surgery performed in the study eye within 90 days before screening;
8. Previous treatment with photodynamic therapy (within 120 days of screening), external-beam radiotherapy, macular laser photocoagulation, macular surgery, or transpupillary thermotherapy;
9. Systemic anti-VEGF therapy administered within 90 days before the first dose;
10. Pregnant or lactating women;
11. Known hypersensitivity or contraindication to any study-related procedure drugs;
12. History of severe cardiac disease, symptomatic congestive heart failure, unstable angina, acute coronary syndrome, myocardial infarction, coronary revascularization, thrombotic event, or bleeding episode within 6 months prior to the start of study drug, uncontrolled hypertension (systolic blood pressure> 150 mmHg and/or diastolic blood pressure > 100 mmHg on optimal medical therapy), or ventricular arrhythmia requiring ongoing treatment;
13. Stroke within 12 months or transient ischemic attack within 6 months of enrolment；
14. Poorly controlled diabetes (HbA1c ≥ 12 %);
15. Other protocol-specified exclusion criteria may apply.